Back to top

Climb Bio’s Budoprutug Trial Completion Sets Stage for Next Investor Catalyst

Climb Bio, Inc. ($CLYM) announced an update on their ongoing clinical study. Climb Bio, Inc. (CLYM) has completed a Phase 1 study called “A Phase 1...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Climb Bio, Inc. (CLYM)